Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited

Constantinescu, Cris S. and Gershkovich, Pavel (2018) Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited. European Journal of Neurology . ISSN 1351-5101

[img] PDF - Repository staff only until 10 April 2019. - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (120kB)

Abstract

Cannabinoids are compounds with pleiotropic properties that act on the cannabinoid receptors, CB1 and CB2, and are divided into endocannabinoids, the endogenous ligands of these receptors, synthetic cannabinoids and phytocannabinoids. The latter are derived from the plant Cannabis sativa. The therapeutic and psychoactive properties of this plant have been observed and used for centuries. Of the over 60 compounds that are unique to Cannabis sativa, the substances that have been attributed the greatest therapeutic potential are Δ9‐ tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which, used alone or combined with each other, have become approved drugs.

Item Type: Article
Additional Information: This is the peer reviewed version of the following article, which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.13658. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Clinical Neuroscience
University of Nottingham, UK > Faculty of Science > School of Pharmacy
Identification Number: https://doi.org/10.1111/ene.13658
Depositing User: Eprints, Support
Date Deposited: 09 Apr 2018 12:16
Last Modified: 01 May 2018 15:51
URI: http://eprints.nottingham.ac.uk/id/eprint/51035

Actions (Archive Staff Only)

Edit View Edit View